SCHEMBL21540

SCHEMBL21540

COc1ccccc1OC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.59
CA2 P00918 3/20 0.59
CA12 O43570 2/20 0.59
CA7 P43166 2/20 0.59
CA9 Q16790 2/20 0.59
CA14 Q9ULX7 2/20 0.59
CA4 P22748 1/20 0.59
POLB P06746 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HTT P42858 2/20 0.55
KMT2A Q03164 1/20 0.55
LMNA P02545 1/20 0.53
ATM Q13315 2/20 0.50
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
PRSS1 P07477 1/20 0.49
ACR P10323 1/20 0.49
BCHE P06276 1/20 0.49
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143632 0.88 KDM4E (0.46) CA1CA2CA12CA7CA9
Glycerin SCHEMBL1486877 0.86 LMNA (0.58) CA1CA2CA12CA7CA9
1,2-Dimethoxybenzene SCHEMBL27679751 0.85 CA1 (0.72) CA1CA2CA12CA7CA9
SCHEMBL8765509 0.85 ALDH1A1 (0.53) CA1CA2CA12CA7CA9
Guaiacol Carbonate SCHEMBL29750682 0.84 CA1 (0.62) CA1CA2CA12CA7CA9
Guaiacol Carbonate SCHEMBL21541 0.84 CA1 (0.62) CA1CA2CA12CA7CA9
SCHEMBL30909436 0.84 CA1 (0.62) CA1CA2CA12CA7CA9
SCHEMBL8579858 0.84 CA1 (0.62) CA1CA2CA12CA7CA9
1,2-Dimethoxybenzene SCHEMBL27470563 0.83 CA1 (0.68) CA1CA2CA12CA7CA9
SCHEMBL27853483 0.83 CA1 (0.54) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024846-A Method for degrading polycarbonate by using phenol catalyst 中国科学院青岛生物能源与过程研究所 2023-11-10 CN claimed
CN-109988296-B Process for producing polycarbonate polyol and polycarbonate polyol composition 财团法人工业技术研究院 2021-09-10 CN claimed
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 WO claimed
US-10689488-B2 Method for preparing polycarbonate polyol and composition comprising the polycarbonate polyol INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2020-06-23 US claimed
CN-111138406-A Sulfonium sulfonate photo-acid generator synthesized from guaiol and synthesis method thereof 上海博栋化学科技有限公司 2020-05-12 CN claimed
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2020-02-13 US claimed
CN-109988296-A The preparation method and polycarbonate polyol composition of polycarbonate polyol 财团法人工业技术研究院 2019-07-09 CN claimed
US-20190202981-A1 METHOD FOR PREPARING POLYCARBONATE POLYOL AND COMPOSITION COMPRISING THE POLYCARBONATE POLYOL INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2019-07-04 US claimed
US-9622969-B2 Polymer conjugated protein micelles SOUTH DAKOTA STATE UNIV (US) 2017-04-18 US claimed
EP-2154138-B1 NOVEL COMPOUNDS FOR TREATMENT OF PSYCHOTIC DISORDERS, PREPARATION METHODS AND USES THEREOF LI YOUXIN (CN) 2015-08-19 EP claimed
US-20140370110-A1 POLYMER CONJUGATED PROTEIN MICELLES SOUTH DAKOTA STATE UNIVERSITY (US) 2014-12-18 US claimed
EP-2729136-A1 DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION Biocopea Limited (GB) 2014-05-14 EP claimed
EP-2608847-A1 THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY Biocopea Limited (GB) 2013-07-03 EP claimed
WO-2013004999-A1 DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION BIOCOPEA LIMITED (GB) 2013-01-10 WO claimed
WO-2012025761-A1 THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY BIOCOPEA LIMITED (GB) 2012-03-01 WO claimed
EP-4519340-B1 PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING COVESTRO DEUTSCHLAND AG (DE) 2026-04-01 EP disclosed
EP-4022391-B1 HEAT SENSITIVE RECORDING MATERIAL WITH NON-PHENOLIC COLOR DEVELOPERS SOLENIS TECHNOLOGIES CAYMAN LP (KY) 2026-03-04 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed
EP-0055313-A1 Guaiacol and derivatives; compositions thereof and use in a method of treatment ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE (CH) 1982-07-07 EP disclosed
US-938132-A GUAIACOL CARBONATE SULFO-ACID DERIVATIVE. BOEHRINGER SOHN INGELHEIM (DE) 1909-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS GSTK1, GSTO1, GSTM2 CA1 725/4885CA2 2428/4885CA12 1970/4885
US-20140370110-A1 POLYMER CONJUGATED PROTEIN MICELLES MTDH, PSMG3, GHITM CA1 3087/4885CA2 4462/4885CA12 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.